



香港中文大學醫學院  
**Faculty of Medicine**  
The Chinese University of Hong Kong



香港中文大學  
The Chinese University of Hong Kong

# Rapid Detection of COVID-19 by CRISPR-Cas Systems

Presenter: **YANG Jun**, Year 3 PhD Student


Supervisor: **Prof. Margaret Ip**

Joint Graduate Student Seminar

Department of Microbiology, Faculty of Medicine, CUHK

14 December 2021

# Introduction of COVID-19



The coronavirus disease 2019 (COVID-19) pandemic is caused by severe acute respiratory disease coronavirus 2 (SARS-CoV-2), which has led to 270 million confirmed cases and 5.3 million deaths globally as of 13 December, 2021 (<https://www.worldometers.info/coronavirus/>).


Rapid and massive detection plays vital role in patient management and curbing disease transmission.

## Physical and genome structure of SARS-CoV-2

(A) Diagram of the SARS-CoV-2 virion.

(B) Genome organization and proteins with known or unknown functions.

# Rapid detection of COVID-19



# Introduction of CRISPR-Cas


 NOBELPRISET I KEMI 2020  
THE NOBEL PRIZE IN CHEMISTRY 2020

 KUNGL. VETENSKAPS-  
AKADEMIEN  
THE ROYAL SWEDISH ACADEMY OF SCIENCES

|   |   |
|---|---|
|  <p><small>Photo: Hoffmann &amp; Parvitz</small></p> |  <p><small>Photo: UC Berkeley/Doudna Lab</small></p> |
| <b>Emmanuelle Charpentier</b>   | <b>Jennifer A. Doudna</b>   |
| Born in France, 1968  | Born in the USA, 1964   |
| Max Planck Unit for the Science of Pathogens, Germany   | University of California, Berkeley, USA<br>Howard Hughes Medical Institute  |



# Features of the CRISPR-Cas adaptive immune system



CRISPR: clustered regularly interspaced short palindromic repeats

Cas: CRISPR-associated proteins


The CRISPR-Cas system with sequence-specific defense against virus and plasmid DNA

**Key**

- Protospacer
- PAM (Protospacer adjacent motif)
- Repeat
- Spacer
- Transcription start


Devaki Bhaya *et al.*, Annu Rev Genet, 2011

# Workflow of CRISPR-Cas9/Cas12 system



Zetsche *et al.*, Cell, 2015


## Non-Homologous End Joining (NHEJ) and Homology Directed Repair (HDR)




adjacent  
) is necessary

Jeffrey D Sander *et al.*, Nat Biotechnol, 2014


# Introduction of CRISPR-Cas



Class 2, type II



Class 2, type V



Class 2, type VI


CRISPR-Cas systems have been developed as the next-generation POC testing for nucleic acid detection because of the high sensitivity and specificity of the CRISPR-Cas systems.

# Mechanism of CRISPR-Cas9 detection (FELUDA)

FELUDA: FnCas9 Editor Linked Uniform Detection Assay


FnCas9: Cas9 from *Francisella novicida*

dFnCas9: catalytically dead FnCas9, can bind to targets but can not cleave




FAM labelled CRISPR-dFnCas9  
+ Biotinylated targets

FAM labelled CRISPR-dFnCas9  
+ Biotinylated targets





Milenia HybridDetect lateral flow strip



Azhar M, *et al*, Biosens Bioelectron, 2021

Crannell ZA *et al*, Anal. Chem. 2014

# CRISPR-Cas9 detection (FELUDA)




LoD: ~10 copies per reaction  
85.3% sensitivity and 96.7% specificity  
473 clinical samples (81 positive samples)


Azhar M *et al*, Biosens Bioelectron, 2021

# Mechanism of CRISPR-Cas12/13 detection


**Collateral cleavage activity:** RNA-guided target binding unleashes indiscriminate ssDNA or ssRNA cleavage activity that completely degrades ssDNA and ssRNA molecules.



Gootenberg JS *et al*, Science, 2018.




Kellner MJ *et al*, Nat Protoc, 2019



Broughton JP *et al*, Nat Biotechnol, 2020

# DETECTR: DNA endonuclease-targeted CRISPR *trans* reporter



LOD: ~10 copies/ $\mu$ L


95.8% sensitivity and 100% specificity

78 clinical samples (36 positive samples)

32-42 min from RNA to result

Broughton JP *et al*, Nat Biotechnol, 2020

# All-In-One Dual CRISPR-Cas12a (AIOD-CRISPR) assay






LbaCas12a: Cas12a from *Lachnospiraceae* bacterium ND2006

Ding X, *et al*, Nat Commun, 2020

# All-In-One Dual CRISPR-Cas12a (AIOD-CRISPR) assay

Visual detection in a portable LED blue transilluminator (Immediately)




40 min from RNA to result

AIOD-CRISPR LOD: 3 copies

Consistent (100%) with result by RT-PCR 28 clinical swab samples (8 positive)

Ding X, *et al*, Nat Commun, 2020

# SHERLOCK One-Pot Testing (STOPCovid.v2)



AapCas12b: thermostable Cas enzyme from *Alicyclobacillus acidiphilus*, it can function up to 65 °C

It takes 45 min (fluorescence) or 80 min (lateral flow) from sample to result

STOPCovid.v2 LOD:  
33 (fluorescence) or 83 (lateral flow) copies /mL


1/30 (fluorescence) or 1/12 (lateral flow) of RT-qPCR test (1000 copies/mL)

93.1% sensitivity and 98.5% specificity  
402 clinical samples (202 positive samples)

Joung J *et al*, N. Engl. J. Med. 2020

# CRISPR-Cas13-based assay

LwaCas13a: Cas13a from *Leptotrichia wadei*



LoD: 42 copies per reaction


100% sensitivity and 100% specificity by fluorescence readout

97% sensitivity and 100% specificity by lateral-flow readout

154 clinical samples (81 positive samples)

Patchsung M *et al*, Nat Biomed Eng, 2020

# Amplification-free detection by CRISPR-Cas13a



LbuCas13a: Cas13a homolog from *Leptotrichia buccalis*

The fluorescence signal can be amplified by using three different gRNAs

Direct detection of SARS-CoV-2 from extracted RNA with a mobile phone camera, it can be used to directly quantify viral load

**LoD: 100 copies/ $\mu$ L within 30 min**

Detect 5 positive clinical samples in under 5 min (ranging from  $3.2 \times 10^5$ – $1.65 \times 10^3$  copies/ $\mu$ L)

Fozouni P *et al*, Cell, 2021

## Conclusions and perspectives

---

1. The LoD, specificity, and sensitivity of CRISPR-Cas based detection platform is comparable with RT-qPCR and can be faster.
2. CRISPR-Cas based diagnostic platforms do not need expensive equipment, so they can be easily used in areas with poor resources.
3. LAMP and RPA are the most common isothermal amplification systems used in POC testing. When combine with CRISPR-Cas, the drawbacks of LAMP and RPA (primer dimer and nonspecific amplification) can be overcome.
4. CRISPR-Cas based diagnostic platforms are good for qualitative detection but can not provide quantitative information except the amplification-free detection by CRISPR-Cas13a.

# References

---

1. Safiabadi TaliSH, LeBlanc JJ, Sadiq Z, et al. Tools and techniques for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 detection. *Clin Microbiol Rev* 2021; 34: 1–63.
2. Bhaya D, Davison M, Barrangou R. CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. *Annu Rev Genet* 2011; 45: 273–97.
3. Addgene. CRISPR 101 : A Desktop Resource Created and Compiled by Addgene. Addgene 2016; 2016: 1–125.
4. Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. *Nat Biotechnol* 2014; 32: 347–55.
5. Zetsche B, Gootenberg JS, Abudayyeh OO, et al. Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System. *Cell* 2015; 163: 759–71.
6. Knott GJ, Doudna JA. CRISPR-Cas guides the future of genetic engineering. *Science* (80- ) 2018; 361: 866–9.
7. Kumar M, Gulati S, Ansari AH, et al. FnCas9-based CRISPR diagnostic for rapid and accurate detection of major SARS-CoV-2 variants on a paper strip. *Elife* 2021; 10. DOI:10.7554/eLife.67130.
8. Azhar M, Phutela R, Kumar M, et al. Rapid and accurate nucleobase detection using FnCas9 and its application in COVID-19 diagnosis. *Biosens Bioelectron* 2021; 183: 113207.
9. Crannell ZA, Castellanos-Gonzalez A, Irani A, Rohrman B, White AC, Richards-Kortum R. Nucleic acid test to diagnose cryptosporidiosis: Lab assessment in animal and patient specimens. *Anal Chem* 2014; 86: 2565–71.

# References

---


10. Gootenberg JS, Abudayyeh OO, Kellner MJ, Joung J, Collins JJ, Zhang F. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a and Csm6. *Science* (80- ) 2018; 360: 439–44.
11. Kellner MJ, Koob JG, Gootenberg JS, Abudayyeh OO, Zhang F. SHERLOCK: nucleic acid detection with CRISPR nucleases. *Nat Protoc* 2019; 14: 2986–3012.
12. Broughton JP, Deng X, Yu G, et al. CRISPR–Cas12-based detection of SARS-CoV-2. *Nat Biotechnol* 2020; 38: 870–4.
13. Ding X, Yin K, Li Z, et al. Ultrasensitive and visual detection of SARS-CoV-2 using all-in-one dual CRISPR-Cas12a assay. *Nat Commun* 2020; 11: 1–10.
14. Joung J, Ladha A, Saito M, et al. Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing. *N. Engl. J. Med.* 2020; 383: 1492–4.
15. Patchsung M, Jantarug K, Pattama A, et al. Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA. *Nat Biomed Eng* 2020; 4: 1140–9.
1. Fozouni P, Son S, Díaz de León Derby M, et al. Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy. *Cell* 2021; 184: 323-333.e9.

***Thank you for your attention !***

# Mechanism of CRISPR-Cas9 detection (FELUDA)

FELUDA: FnCas9 Editor Linked Uniform Detection Assay


## Gel Based Nucleic Acid Detection:



FnCas9 is one of Cas9 with high mismatch sensitivity both under *in vitro* and *in vivo* conditions.


Kumar M, *et al*, Elife, 2021

# CRISPR-Cas9 detection (FELUDA)



Azhar M, *et al*, Biosens Bioelectron, 2021

# Amplification-free detection by CRISPR-Cas13a



Schematic of mobile phone-based microscope for fluorescence detection